Palatin Tech - PTN STOCK NEWS

Palatin Technologies (NYSE American: PTN) announced the publication of a manuscript in the International Journal of Molecular Sciences, highlighting PL8331’s therapeutic effects in diabetic retinopathy and uveitis. The study, funded by Palatin and NIH, demonstrated PL8331's efficacy as a melanocortin agonist in mouse models, showing promise in reducing inflammation and preserving retinal structure. Notably, in the EAU model, PL8331 protected retinal cells from damage, while in the DR model, it enhanced cell survival and suppressed VEGF, crucial in DR pathology. The findings underscore the potential of melanocortin agonists in treating inflammatory eye diseases and support future clinical development for Palatin. CEO Carl Spana emphasized the growing pre-clinical data supporting these prospects.

Palatin Technologies, Inc. (NYSE American: PTN) announced a study published in Frontiers in Immunology, highlighting the therapeutic effects of its oral formulation, PL8177, in preclinical models of inflammatory bowel disease. The study reports that PL8177 remains gut-restricted, showing promising results such as reduced immune cell infiltration and improved colon structure. Pharmacokinetic studies indicated that PL8177 is effective in the colon without systemic absorption. The company is currently enrolling patients in a Phase 2 clinical trial for ulcerative colitis. Initial results from the trial are expected in mid-2023, with final data anticipated later in the year.

On February 28, 2023, Palatin Technologies, Inc. (NYSE American: PTN) announced the issuance of U.S. Patent No. 11,590,209 for the use of bremelanotide in patients with controlled hypertension. This patent strengthens the intellectual property surrounding Vyleesi, its FDA-approved treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women. The patent extends to April 29, 2041, enhancing the company's competitive positioning in the market. CEO Carl Spana expressed optimism regarding the patent’s contribution to Palatin's innovation efforts and the expansion of its Vyleesi portfolio, which the company is actively seeking to commercialize further.

Palatin Technologies (PTN) reported financial results for the fiscal second quarter ending December 31, 2022, highlighting a net product revenue of approximately $1 million for Vyleesi®, marking an 18% increase over the previous quarter and a staggering 1,323% increase compared to last year. Operating expenses decreased to $6.6 million from $8.8 million, contributing to a reduced net loss of $1.4 million, down from $8.7 million a year prior. The company closed a $10 million direct offering and received $4.7 million in non-dilutive funding. Key clinical trials, including the Phase 3 study of PL9643 for dry eye disease, are ongoing, with topline results expected in mid-2023.

Palatin Technologies, Inc. (NYSE American: PTN) will announce its second quarter fiscal year 2023 operating results on February 15, 2023, before the U.S. market opens. A conference call and live audio webcast will follow the announcement at 11:00 a.m. ET, featuring insights from the executive management team regarding operating results and developmental updates. The press release for the fiscal results will be available at 7:30 a.m. ET on February 15. Investors can access the audio webcast on Palatin's website, providing crucial information about the company's performance and future strategies.

Palatin Technologies announced the initiation of a Phase 2b clinical trial, known as the BREAKOUT Study, for bremelanotide in treating diabetic kidney disease. This study aims to enroll up to 45 subjects and evaluates the effectiveness of bremelanotide combined with RAAS inhibition therapy. The primary endpoint is a 50% reduction in urine protein/creatinine (UP/Cr) ratio after six months. Patient dosing begins in January 2023, with expected completion of enrollment by Q3 2023 and topline data by Q1 2024. This clinical program marks Palatin’s third clinical initiative utilizing melanocortin agonists, focusing on addressing diabetic nephropathy, a significant cause of renal disease.

Palatin Technologies (PTN) has secured approximately $4.7 million in non-dilutive funding through New Jersey's Net Operating Loss (NOL) Program. This program enables qualified technology companies to convert state operating losses into cash. To date, Palatin has received about $18 million from this program. CFO Stephen T. Wills expressed gratitude for the support from the NJ Economic Development Authority, highlighting the funding's role in advancing drug development efforts. Palatin focuses on creating first-in-class medicines targeting the melanocortin receptor system, aiming to address significant unmet medical needs.

Palatin Technologies (PTN) announced the publication of a study in Frontiers in Immunology highlighting the therapeutic effects of PL-8177 on inflammatory conditions, including arthritis. Conducted with The William Harvey Research Institute and Queen Mary University in London, the study confirmed PL-8177's potential as a melanocortin receptor 1 agonist, demonstrating anti-inflammatory properties in rodent models. The ongoing Phase 2 clinical trial for PL-8177 in ulcerative colitis is set for interim assessment in Q1 2023, with topline data expected by Q2 2023, signifying promising advancements in treating chronic inflammatory diseases.

Palatin Technologies (PTN) disclosed preliminary sales results for Vyleesi® for the fiscal second quarter ended December 31, 2022. The company reported a 15.4% increase in net product revenue, totaling $1.0 million, and a striking 1,290% increase compared to the same quarter in 2021. Gross product sales reached $2.6 million, a 238% increase year-over-year. Additionally, prescriptions dispensed rose by 11.5% quarter-over-quarter, and 134% year-over-year. While management is optimistic about growth, the preliminary nature of the data could lead to significant adjustments.